https://www.shahcapital.com/vitamin-shoppe-to-appoint-new-independent-directors-to-board/2018-04-23T08:15:44+00:00https://www.shahcapital.com/top-ten-holdings-of-himanshu-shah/2022-02-16T17:37:41+00:00https://www.shahcapital.com/marius-pharmaceuticals-receives-fda-approval-of-kyzatrex-an-oral-testosterone-replacement-therapy/2025-11-24T21:21:56+00:00https://www.shahcapital.com/shah-outperforms-market/2025-11-19T17:36:02+00:00https://www.shahcapital.com/activism-and-alpha-himanshu-shahs-blueprint-for-long-term-success-at-shah-capital/2024-10-14T12:00:50+00:00https://www.shahcapital.com/marius-pharmaceuticals-helps-drive-fdas-landmark-testosterone-label-update-removing-black-box-warning/2025-11-24T21:21:52+00:00https://www.shahcapital.com/veon-welcomes-letter-from-its-shareholder-shah-capital-reiterates-commitment-to-shareholder-value-creation/2024-10-21T12:00:58+00:00https://www.shahcapital.com/shock-policies-and-global-ramifications/2026-04-02T18:30:48+00:00https://www.shahcapital.com/emeren-signed-merger-agreement-with-shah-capital-to-go-private/2025-06-20T13:07:35+00:00https://www.shahcapital.com/fda-testosterone-panel-call-for-overhaul-of-outdated-testosterone-therapy-regulations/2025-12-16T19:40:03+00:00https://www.shahcapital.com/shurya-vitra-ltd-privatizes-emeren/2025-12-16T19:37:20+00:00https://www.shahcapital.com/the-contrarian-investor/2026-03-24T14:57:48+00:00https://www.shahcapital.com/letter-to-novavax-leadership/2026-04-08T18:43:02+00:00